Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ

This article was originally published in The Tan Sheet

Executive Summary

Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality
Advertisement

Related Content

ODS Evidence-Based Review Program Recruits NCI Official
ODS Evidence-Based Review Program Recruits NCI Official
AHRQ Ephedra Evidence Report Targeted For August 2002 Release

Topics

Advertisement
UsernamePublicRestriction

Register

PS094629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel